Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aluminum phthalocyanine chloride** is a second-generation, hydrophobic, organometallic photosensitizer widely used in photodynamic therapy (PDT), especially for cancer and antimicrobial indications. When activated by light (typically 660–680 nm), it produces reactive oxygen species (ROS) that result in cytotoxic effects, mainly by inducing oxidative damage and cell death in the targeted tissues. Its main limitation is high hydrophobicity, which leads to the risk of aggregation in aqueous media and poor bioavailability; various nanoemulsion and hydrogel delivery systems have been developed to overcome these obstacles. It is not a systemically approved pharmaceutical but is studied primarily for topical or localized photodynamic therapies in preclinical and investigational clinical contexts[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aluminum phthalocyanine chloride.